HZNP up +2.29% percent Today $HZNP High is at 12.64 and the Low 12.13 with current volume of 394,384.
Recent News posted below.
Horizon Pharma Inc HZNP other info.
http://investorshangout.com/Horizon-Pharma-Inc-HZNP-54397/
HZNP Horizon Pharma Inc Recent Headline News
Horizon Pharma discloses pricing of secondary offering of 11.66m ordinary shares
M2 - Mon Nov 17, 6:04AM CST
Biopharmaceutical company Horizon Pharma (NasdaqGS:HZNP) said on Friday that it has priced a secondary public offering of 11,660,445 of its ordinary shares.
HZNP: 12.47 (+0.22)
Horizon Pharma: A Strong Buy Following The Q3 Report
ONeil Trader - at Seeking Alpha - Sat Nov 15, 8:39AM CST
HZNP: 12.47 (+0.22)
Horizon Pharma plc Announces Pricing of Secondary Offering of Ordinary Shares by Selling Shareholders
Marketwired - Fri Nov 14, 7:03AM CST
Horizon Pharma plc (NASDAQ: HZNP), a specialty biopharmaceutical company with a portfolio of products in arthritis, inflammation and orphan diseases, today announced the pricing of a previously announced underwritten secondary offering of 11,660,445 of its ordinary shares held by certain of its existing shareholders, offered at a price to the public of $12.05 per share. Horizon Pharma plc is not issuing new ordinary shares and will not receive any proceeds from the sale of ordinary shares by the selling shareholders in the offering. The offering is expected to close on or about November 19, 2014, subject to customary closing conditions.
HZNP: 12.47 (+0.22), MS: 35.57 (-0.12)
Strong Earnings And Low Valuation To Catalyze Horizon Pharma
David Zanoni - at Seeking Alpha - Thu Nov 13, 8:30AM CST
HZNP: 12.47 (+0.22)
Horizon Pharma plc Announces Proposed Secondary Offering of Ordinary Shares by Selling Shareholders
Marketwired - Thu Nov 13, 6:03AM CST
Horizon Pharma plc (NASDAQ: HZNP), a specialty biopharmaceutical company with a portfolio of products in arthritis, inflammation and orphan diseases, today announced a proposed underwritten secondary offering of 11,660,445 of its ordinary shares held by certain of its existing shareholders. Horizon Pharma plc is not issuing new ordinary shares and will not receive any proceeds from the sale of ordinary shares by the selling shareholders in the offering.
HZNP: 12.47 (+0.22), MS: 35.57 (-0.12)
Horizon Pharma plc Announces Clinical Data on RAYOS(R) (Prednisone) Delayed-Release Tablets and VIMOVO(R) (Naproxen/Esomeprazole Magnesium) to Be Presented at the American College of Rheumatology Annual Meeting
Marketwired - Wed Nov 12, 3:09PM CST
Horizon Pharma plc (NASDAQ: HZNP) today announced that four abstracts related to RAYOS (prednisone) delayed-release tablets and one abstract on VIMOVO (naproxen/esomeprazole magnesium) will be presented during the American College of Rheumatology (ACR) and Association of Rheumatology Health Professionals (ARHP) Annual Scientific Meeting taking place November 15 to 19, 2014 in Boston, MA.
HZNP: 12.47 (+0.22)
Horizon Pharma plc Announces Favorable Markman Ruling in RAYOS(R) (prednisone) Delayed-Release Tablets Patent Infringement Litigation
Marketwired - Wed Nov 12, 7:05AM CST
Horizon Pharma plc (NASDAQ: HZNP), a specialty biopharmaceutical company with a portfolio of products in arthritis, inflammation and orphan diseases, today announced that a favorable Markman ruling has been issued by Judge Joseph E. Irenas of the United States District Court for the District of New Jersey in the patent infringement lawsuit filed by Horizon against Watson Laboratories, Inc. for an Abbreviated New Drug Application ("ANDA"
to market a generic version of RAYOS.
HZNP: 12.47 (+0.22)
Horizon Pharma plc to Present at the Stifel 2014 Healthcare Conference
Marketwired - Tue Nov 11, 3:05PM CST
Horizon Pharma plc (NASDAQ: HZNP), a specialty biopharmaceutical company with a portfolio of products in arthritis, inflammation and orphan diseases, today announced that Robert F. Carey, executive vice president and chief business officer, will present at the Stifel 2014 Healthcare Conference on Tuesday, November 18, 2014 at 4:45 p.m. Eastern Time in New York, NY. Mr. Carey will provide an overview of the Company and its corporate activities.
HZNP: 12.47 (+0.22)
Horizon Pharma's (HZNP) CEO Timothy Walbert on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 06, 12:20PM CST
HZNP: 12.47 (+0.22)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 8:14AM CST
ACAS: 15.00 (-0.11), WWWW: 16.55 (-0.08), PHMD: 2.34 (-0.06), RVLT: 1.52 (-0.09), SNMX: 5.14 (-0.33), PBR: 9.32 (-0.63), QCOM: 70.63 (-0.22), GNRC: 41.91 (+0.04), HZNP: 12.47 (+0.22), PESI: 4.38 (-0.10), WAC: 16.67 (+0.08), TRUE: 17.71 (-0.04), KATE: 28.83 (-0.10), DRYS: 1.40 (-0.01), Z: 117.80 (+4.09), WFM: 47.48 (+0.37), SWIR: 38.54 (+0.23), COT: 6.81 (+0.09), CSOD: 30.08 (+0.18), MCP: 1.28 (+0.03), GNW: 9.34 (-0.07), CECO: 5.68 (-0.21), GERN: 3.00 (+0.24), NDLS: 23.20 (-0.28), MEET: 1.81 (-0.01), AEZS: 0.57 (+0.01), DATA: 83.73 (-1.10), PLNR: 7.05 (+0.36), SZYM: 3.41 (-0.05)
Horizon Pharma elects John J. Kody as EVP
M2 - Thu Nov 06, 7:22AM CST
Biopharmaceutical company Horizon Pharma (NasdaqGS:HZNP) said on Thursday that its board has named John J. Kody as its executive vice president and chief commercial officer, as well as to its executive committee.
HZNP: 12.47 (+0.22), DHR: 82.42 (+0.19)
Horizon Pharma (HZNP) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Nov 06, 6:55AM CST
HZNP: 12.47 (+0.22)
Horizon Pharma beats by $0.07, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 6:31AM CST
HZNP: 12.47 (+0.22)
Horizon Pharma plc Reports Third Quarter 2014 Financial Results and Raises Guidance for 2014 and 2015
Marketwired - Thu Nov 06, 6:02AM CST
Horizon Pharma plc (NASDAQ: HZNP) today provided an update on the Company's business and announced financial results for the third quarter and nine months ended September 30, 2014.
HZNP: 12.47 (+0.22)
Horizon Pharma plc Appoints John J. Kody as Executive Vice President and Chief Commercial Officer
Marketwired - Thu Nov 06, 5:30AM CST
Horizon Pharma plc (NASDAQ: HZNP), a specialty biopharmaceutical company with a portfolio of products in arthritis, inflammation and orphan diseases, announced today the Company's Board has appointed John J. Kody, executive vice president and chief commercial officer, reporting to Timothy P. Walbert, chairman, president and chief executive officer, effective November 24, 2014. Mr. Kody brings more than 20 years of executive, general management and commercial experience in the pharmaceutical, biotechnology and medical device industries to Horizon Pharma. He will also be a member of the Company's executive committee.
HZNP: 12.47 (+0.22), DHR: 82.42 (+0.19)
Notable earnings before Thursday’s open
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 4:30PM CST
CYNI: 2.71 (-0.04), AAP: 145.76 (+0.95), DNOW: 28.52 (+0.18), AAON: 20.48 (-0.48), CNQ: 35.66 (-0.34), HSP: 58.33 (+0.05), CNK: 35.62 (-0.04), AMSC: 0.98 (-0.05), AES: 13.67 (+0.20), MWIV: 158.43 (+3.38), BBG: 12.95 (-1.16), HZNP: 12.47 (+0.22), KATE: 28.83 (-0.10), MITL: 10.24 (+0.12), AEE: 43.05 (+0.84), HSIC: 130.68 (+0.53), HII: 107.97 (+0.12), NAVB: 1.26 (+0.10), CECE: 14.10 (-0.44), AKRX: 37.92 (-0.29), COTY: 19.01 (-0.14), GOLD: 69.24 (+0.49), IT: 86.15 (+0.10), HNR: 2.89 (-0.10), KERX: 15.20 (-0.01), CECO: 5.68 (-0.21), HSC: 19.93 (+0.43), AMRC: 8.03 (-0.06), KLIC: 13.77 (-0.19), GEO: 39.28 (-0.64), AINV: 8.20 (+0.01), BCE: 47.37 (+0.50), AZN: 72.46 (-0.39), BCRX: 10.19 (+0.12), CPN: 23.47 (-0.13), BR: 45.12 (+0.05), FUR: 16.93 (+0.08), LIN: 24.00 (-0.04), LMIA: 13.84 (+0.12), CDW: 32.82 (-0.13), CVC: 18.68 (+0.14), AAWW: 41.23 (-0.38), GNRC: 41.92 (+0.05), MPEL: 25.92 (-0.61), DTV: 86.99 (-0.56), APA: 72.33 (-1.02), CRZO: 50.28 (-1.31), BKCC: 8.94 (unch), ERJ: 36.91 (+0.15), AMCX: 62.28 (+0.42), LPI: 17.16 (-0.55), HAIN: 108.38 (+0.11), FSYS: 10.03 (-0.38), GLP: 43.39 (+1.09), AOL: 46.75 (+0.71), FUN: 46.80 (-0.06), BDBD: 9.80 (+0.13)
Will Horizon Pharma (HZNP) Earnings Surprise This Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 2:06PM CST
Horizon Pharma (HZNP), which is scheduled to report third-quarter 2014 results on Nov 6, had delivered a negative earnings surprise of 12.50% last quarter.
PBH: 30.54 (-0.78), HZNP: 12.47 (+0.22), INFI: 14.31 (+0.21), HSP: 58.33 (+0.05)
Horizon Pharma plc Announces DUEXIS(R) Selected as Winner of Chicago Innovation Award
Marketwired - Fri Oct 31, 7:00AM CDT
Horizon Pharma plc (NASDAQ: HZNP), a specialty biopharmaceutical company with a portfolio of products in arthritis, inflammation and orphan diseases, today announced that DUEXIS(R) (ibuprofen/famotidine) has been selected as one of the winners of the 13th annual Chicago Innovation Awards. Last night at Chicago's Harris Theater, Timothy P. Walbert, chairman, president and chief executive officer of Horizon Pharma, received the award with nearly 1,500 business and civic leaders in attendance. The Chicago Innovation Awards, celebrating its 13th year, recognizes the most innovative new products or services brought to market or to public service each year.
HZNP: 12.47 (+0.22)
POZEN receives three patents from USPTO covering VIMOVO delayed-release tablets
M2 - Thu Oct 23, 7:10AM CDT
Pharmaceutical company POZEN Inc (NASDAQ: POZN) declared on Thursday the receipt of three patents from the United States Patent and Trademark Office (USPTO), entitled 'Pharmaceutical Compositions for the Coordinated Delivery of NSAIDs, for VIMOVO (naproxen / esomeprazole magnesium) delayed-release tablets, a US approved product.
HZNP: 12.47 (+0.22), POZN: 9.01 (-0.08)
POZEN Announces Receipt of Three Patents from the United States Patent and Trademark Office
Business Wire - Thu Oct 23, 6:30AM CDT
POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, today announced that it has received three patents from the United States Patent and Trademark Office (USPTO), entitled "Pharmaceutical Compositions for the Coordinated Delivery of NSAIDs" that cover the U.S. approved product VIMOVO(R) (naproxen / esomeprazole magnesium) delayed-release tablets.
HZNP: 12.47 (+0.22), POZN: 9.01 (-0.08)
Recent News posted below.
Horizon Pharma Inc HZNP other info.
http://investorshangout.com/Horizon-Pharma-Inc-HZNP-54397/
HZNP Horizon Pharma Inc Recent Headline News
Horizon Pharma discloses pricing of secondary offering of 11.66m ordinary shares
M2 - Mon Nov 17, 6:04AM CST
Biopharmaceutical company Horizon Pharma (NasdaqGS:HZNP) said on Friday that it has priced a secondary public offering of 11,660,445 of its ordinary shares.
HZNP: 12.47 (+0.22)
Horizon Pharma: A Strong Buy Following The Q3 Report
ONeil Trader - at Seeking Alpha - Sat Nov 15, 8:39AM CST
HZNP: 12.47 (+0.22)
Horizon Pharma plc Announces Pricing of Secondary Offering of Ordinary Shares by Selling Shareholders
Marketwired - Fri Nov 14, 7:03AM CST
Horizon Pharma plc (NASDAQ: HZNP), a specialty biopharmaceutical company with a portfolio of products in arthritis, inflammation and orphan diseases, today announced the pricing of a previously announced underwritten secondary offering of 11,660,445 of its ordinary shares held by certain of its existing shareholders, offered at a price to the public of $12.05 per share. Horizon Pharma plc is not issuing new ordinary shares and will not receive any proceeds from the sale of ordinary shares by the selling shareholders in the offering. The offering is expected to close on or about November 19, 2014, subject to customary closing conditions.
HZNP: 12.47 (+0.22), MS: 35.57 (-0.12)
Strong Earnings And Low Valuation To Catalyze Horizon Pharma
David Zanoni - at Seeking Alpha - Thu Nov 13, 8:30AM CST
HZNP: 12.47 (+0.22)
Horizon Pharma plc Announces Proposed Secondary Offering of Ordinary Shares by Selling Shareholders
Marketwired - Thu Nov 13, 6:03AM CST
Horizon Pharma plc (NASDAQ: HZNP), a specialty biopharmaceutical company with a portfolio of products in arthritis, inflammation and orphan diseases, today announced a proposed underwritten secondary offering of 11,660,445 of its ordinary shares held by certain of its existing shareholders. Horizon Pharma plc is not issuing new ordinary shares and will not receive any proceeds from the sale of ordinary shares by the selling shareholders in the offering.
HZNP: 12.47 (+0.22), MS: 35.57 (-0.12)
Horizon Pharma plc Announces Clinical Data on RAYOS(R) (Prednisone) Delayed-Release Tablets and VIMOVO(R) (Naproxen/Esomeprazole Magnesium) to Be Presented at the American College of Rheumatology Annual Meeting
Marketwired - Wed Nov 12, 3:09PM CST
Horizon Pharma plc (NASDAQ: HZNP) today announced that four abstracts related to RAYOS (prednisone) delayed-release tablets and one abstract on VIMOVO (naproxen/esomeprazole magnesium) will be presented during the American College of Rheumatology (ACR) and Association of Rheumatology Health Professionals (ARHP) Annual Scientific Meeting taking place November 15 to 19, 2014 in Boston, MA.
HZNP: 12.47 (+0.22)
Horizon Pharma plc Announces Favorable Markman Ruling in RAYOS(R) (prednisone) Delayed-Release Tablets Patent Infringement Litigation
Marketwired - Wed Nov 12, 7:05AM CST
Horizon Pharma plc (NASDAQ: HZNP), a specialty biopharmaceutical company with a portfolio of products in arthritis, inflammation and orphan diseases, today announced that a favorable Markman ruling has been issued by Judge Joseph E. Irenas of the United States District Court for the District of New Jersey in the patent infringement lawsuit filed by Horizon against Watson Laboratories, Inc. for an Abbreviated New Drug Application ("ANDA"
to market a generic version of RAYOS. HZNP: 12.47 (+0.22)
Horizon Pharma plc to Present at the Stifel 2014 Healthcare Conference
Marketwired - Tue Nov 11, 3:05PM CST
Horizon Pharma plc (NASDAQ: HZNP), a specialty biopharmaceutical company with a portfolio of products in arthritis, inflammation and orphan diseases, today announced that Robert F. Carey, executive vice president and chief business officer, will present at the Stifel 2014 Healthcare Conference on Tuesday, November 18, 2014 at 4:45 p.m. Eastern Time in New York, NY. Mr. Carey will provide an overview of the Company and its corporate activities.
HZNP: 12.47 (+0.22)
Horizon Pharma's (HZNP) CEO Timothy Walbert on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 06, 12:20PM CST
HZNP: 12.47 (+0.22)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 8:14AM CST
ACAS: 15.00 (-0.11), WWWW: 16.55 (-0.08), PHMD: 2.34 (-0.06), RVLT: 1.52 (-0.09), SNMX: 5.14 (-0.33), PBR: 9.32 (-0.63), QCOM: 70.63 (-0.22), GNRC: 41.91 (+0.04), HZNP: 12.47 (+0.22), PESI: 4.38 (-0.10), WAC: 16.67 (+0.08), TRUE: 17.71 (-0.04), KATE: 28.83 (-0.10), DRYS: 1.40 (-0.01), Z: 117.80 (+4.09), WFM: 47.48 (+0.37), SWIR: 38.54 (+0.23), COT: 6.81 (+0.09), CSOD: 30.08 (+0.18), MCP: 1.28 (+0.03), GNW: 9.34 (-0.07), CECO: 5.68 (-0.21), GERN: 3.00 (+0.24), NDLS: 23.20 (-0.28), MEET: 1.81 (-0.01), AEZS: 0.57 (+0.01), DATA: 83.73 (-1.10), PLNR: 7.05 (+0.36), SZYM: 3.41 (-0.05)
Horizon Pharma elects John J. Kody as EVP
M2 - Thu Nov 06, 7:22AM CST
Biopharmaceutical company Horizon Pharma (NasdaqGS:HZNP) said on Thursday that its board has named John J. Kody as its executive vice president and chief commercial officer, as well as to its executive committee.
HZNP: 12.47 (+0.22), DHR: 82.42 (+0.19)
Horizon Pharma (HZNP) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Nov 06, 6:55AM CST
HZNP: 12.47 (+0.22)
Horizon Pharma beats by $0.07, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 6:31AM CST
HZNP: 12.47 (+0.22)
Horizon Pharma plc Reports Third Quarter 2014 Financial Results and Raises Guidance for 2014 and 2015
Marketwired - Thu Nov 06, 6:02AM CST
Horizon Pharma plc (NASDAQ: HZNP) today provided an update on the Company's business and announced financial results for the third quarter and nine months ended September 30, 2014.
HZNP: 12.47 (+0.22)
Horizon Pharma plc Appoints John J. Kody as Executive Vice President and Chief Commercial Officer
Marketwired - Thu Nov 06, 5:30AM CST
Horizon Pharma plc (NASDAQ: HZNP), a specialty biopharmaceutical company with a portfolio of products in arthritis, inflammation and orphan diseases, announced today the Company's Board has appointed John J. Kody, executive vice president and chief commercial officer, reporting to Timothy P. Walbert, chairman, president and chief executive officer, effective November 24, 2014. Mr. Kody brings more than 20 years of executive, general management and commercial experience in the pharmaceutical, biotechnology and medical device industries to Horizon Pharma. He will also be a member of the Company's executive committee.
HZNP: 12.47 (+0.22), DHR: 82.42 (+0.19)
Notable earnings before Thursday’s open
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 4:30PM CST
CYNI: 2.71 (-0.04), AAP: 145.76 (+0.95), DNOW: 28.52 (+0.18), AAON: 20.48 (-0.48), CNQ: 35.66 (-0.34), HSP: 58.33 (+0.05), CNK: 35.62 (-0.04), AMSC: 0.98 (-0.05), AES: 13.67 (+0.20), MWIV: 158.43 (+3.38), BBG: 12.95 (-1.16), HZNP: 12.47 (+0.22), KATE: 28.83 (-0.10), MITL: 10.24 (+0.12), AEE: 43.05 (+0.84), HSIC: 130.68 (+0.53), HII: 107.97 (+0.12), NAVB: 1.26 (+0.10), CECE: 14.10 (-0.44), AKRX: 37.92 (-0.29), COTY: 19.01 (-0.14), GOLD: 69.24 (+0.49), IT: 86.15 (+0.10), HNR: 2.89 (-0.10), KERX: 15.20 (-0.01), CECO: 5.68 (-0.21), HSC: 19.93 (+0.43), AMRC: 8.03 (-0.06), KLIC: 13.77 (-0.19), GEO: 39.28 (-0.64), AINV: 8.20 (+0.01), BCE: 47.37 (+0.50), AZN: 72.46 (-0.39), BCRX: 10.19 (+0.12), CPN: 23.47 (-0.13), BR: 45.12 (+0.05), FUR: 16.93 (+0.08), LIN: 24.00 (-0.04), LMIA: 13.84 (+0.12), CDW: 32.82 (-0.13), CVC: 18.68 (+0.14), AAWW: 41.23 (-0.38), GNRC: 41.92 (+0.05), MPEL: 25.92 (-0.61), DTV: 86.99 (-0.56), APA: 72.33 (-1.02), CRZO: 50.28 (-1.31), BKCC: 8.94 (unch), ERJ: 36.91 (+0.15), AMCX: 62.28 (+0.42), LPI: 17.16 (-0.55), HAIN: 108.38 (+0.11), FSYS: 10.03 (-0.38), GLP: 43.39 (+1.09), AOL: 46.75 (+0.71), FUN: 46.80 (-0.06), BDBD: 9.80 (+0.13)
Will Horizon Pharma (HZNP) Earnings Surprise This Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 2:06PM CST
Horizon Pharma (HZNP), which is scheduled to report third-quarter 2014 results on Nov 6, had delivered a negative earnings surprise of 12.50% last quarter.
PBH: 30.54 (-0.78), HZNP: 12.47 (+0.22), INFI: 14.31 (+0.21), HSP: 58.33 (+0.05)
Horizon Pharma plc Announces DUEXIS(R) Selected as Winner of Chicago Innovation Award
Marketwired - Fri Oct 31, 7:00AM CDT
Horizon Pharma plc (NASDAQ: HZNP), a specialty biopharmaceutical company with a portfolio of products in arthritis, inflammation and orphan diseases, today announced that DUEXIS(R) (ibuprofen/famotidine) has been selected as one of the winners of the 13th annual Chicago Innovation Awards. Last night at Chicago's Harris Theater, Timothy P. Walbert, chairman, president and chief executive officer of Horizon Pharma, received the award with nearly 1,500 business and civic leaders in attendance. The Chicago Innovation Awards, celebrating its 13th year, recognizes the most innovative new products or services brought to market or to public service each year.
HZNP: 12.47 (+0.22)
POZEN receives three patents from USPTO covering VIMOVO delayed-release tablets
M2 - Thu Oct 23, 7:10AM CDT
Pharmaceutical company POZEN Inc (NASDAQ: POZN) declared on Thursday the receipt of three patents from the United States Patent and Trademark Office (USPTO), entitled 'Pharmaceutical Compositions for the Coordinated Delivery of NSAIDs, for VIMOVO (naproxen / esomeprazole magnesium) delayed-release tablets, a US approved product.
HZNP: 12.47 (+0.22), POZN: 9.01 (-0.08)
POZEN Announces Receipt of Three Patents from the United States Patent and Trademark Office
Business Wire - Thu Oct 23, 6:30AM CDT
POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, today announced that it has received three patents from the United States Patent and Trademark Office (USPTO), entitled "Pharmaceutical Compositions for the Coordinated Delivery of NSAIDs" that cover the U.S. approved product VIMOVO(R) (naproxen / esomeprazole magnesium) delayed-release tablets.
HZNP: 12.47 (+0.22), POZN: 9.01 (-0.08)
